| Literature DB >> 33306052 |
Akram Hashemi1, Fatemeh Bahmani1, Saeedeh Saeedi Tehrani1, Mina Forouzandeh1, Jalil Koohpayehzadeh2, Mortaza Ashrafi1, Majid Reza Khalajzadeh1, Seyed Abbas Motevalian3.
Abstract
Background: Research ethics committees are comprised of policymakers, supervisors, and decision-makers and aim at increasing adherence to professional ethics standards in conducting health-related research. The existential philosophy of these committees is to preserve the patients' health, maintain and promote public trust in health care providers, protect the rights of both patients and health care providers, and promote organizational ethics. However, this task can be complex and challenging during a public health emergency. Research ethics committees set the standard of research in the emergency situations through defining which research has the potential to promote the quality of response to a public health emergency.Entities:
Keywords: COVID-19; Pandemic; Research ethics committee
Year: 2020 PMID: 33306052 PMCID: PMC7711043 DOI: 10.34171/mjiri.34.87
Source DB: PubMed Journal: Med J Islam Repub Iran ISSN: 1016-1430
Challenges and solutions of ethics reviewers
| Research ethics criteria | Reviewer/committee concern | Recommended solutions |
| Scientific design | Previous scientific evidence is insufficient (Clinical information or pharmaceutical mechanism has not been fully disclosed.). | Evaluation of clinical information and pharmaceutical mechanisms by scientific reviewers of the research ethics committee |
| The objectives are hardly achievable with respect to available facilities | Assessing the feasibility of proposed research procedures by the research ethics committee | |
| Inclusion and exclusion criteria | Failure to meet appropriate inclusion and exclusion criteria | The criteria are to be explained in an objective and measurable way in both control and case groups. |
| Research procedures | Absence of adequate or appropriate expertise to perform the research procedures | Adding a researcher with relevant expertise to the research group |
| Not including procedures to monitor adverse events of the research interventions | Including procedures to monitor adverse events of the research interventions | |
| Absence of procedures for posttrial provision of research interventions, such as special psychological or educational training for the control group | Employing procedures for posttrial provisions | |
| Risk/burden and benefit | Failure to provide evidence on efficacy and safety required for therapeutic intervention | Inserting and explaining scientific evidence on efficacy and safety of intervention in literature review |
| Failure to balance the benefits / risks of unapproved interventions for patients | After obtaining informed consent, the researcher is allowed to enter only those patients into the study whose clinical condition worsened, despite receiving treatment protocols notified by the Ministry of Health. | |
| The benefits to the patients or the future community are not clear. | Disclosing potential benefits for the community | |
| Research subject compensation or reimbursement of costs | The PI/funder has not provided compensation to participants for the potential serious adverse events. |
-According to chapter 2 of the ethics guidelines for clinical trials, the author is responsible for compensating patients. Thus, the author is supposed to commit to obtain the accident insurance policy from the sponsor of the project and submit it to the Research Ethics Committee. |
| Risk of coercion regarding the fact that patients participate only due to economic issues and reimbursement of costs |
-Review of ethical issues by ethics committee | |
| Process of obtaining informed consent | Incomplete insertion of the process of obtaining informed consent | Writing down the time, place, and the person who explains information about the project to patients or their families. Stating the way how to get an alternative decision-maker to consent to patient participation in research, when the patient is not qualified to give informed consent. |
Workgroup and study type
| Workgroup and study type | Number |
| Epidemiology and public health research | 32 |
| Clinical research | 28 |
| Basic science and virology research | 16 |
| Research into staff health maintenance, particularly mental and educational health | 7 |
Reviewer/committee concerns regarding consent document and recommended solutions
| Criteria for consent document | Reviewer/committee concern | Recommended solutions |
| Purpose of research | Study information is stated in a way that therapeutic misconception may occur. | Providing the patient with ample opportunity to consult before making a decision |
| Study procedures |
Participation stages are not clearly described. | The type of research intervention and patient collaboration should be clearly stated both in the proposal and in the informed consent. |
| Disclosure of potential risk/burden |
The research risks are not fully explained. |
- The forms of informed consent and the report of adverse events will be examined by the ethics committee in research. |
| Disclosure of benefits | Statement of the benefits can be subject to undue influence through persuading the individuals to participate in research to identify and discover new Coronavirus treatment without having sufficient evidence | Accurate evaluation and scientific review of the suggested treatment by scientific referees collaborating with the research ethics committee |